Information  X 
Enter a valid email address

Medica Group PLC (MGP)


Wednesday 16 June, 2021

Medica Group PLC

AGM Statement

RNS Number : 0049C
Medica Group PLC
16 June 2021

16 June 2021


Medica Group Plc


AGM Statement


Medica Group PLC (LSE:MGP, "Medica" or the "Company"), the UK and Ireland market leader in the provision of teleradiology services, is holding its Annual General Meeting ("AGM") at 10.30am today


Consistent with current public safety measures, shareholders will not be able to attend the meeting in person. However, the Company has made arrangements for shareholders to attend the meeting remotely by visiting the AGM section of our website at: . Any questions submitted by shareholders to the Company in advance or raised electronically during the meeting will be addressed during the meeting.


Roy Davis, Chairman of Medica, will provide the following update at the AGM: 


"Over the last year, Medica has built strong foundations for future growth by building reporter capacity, implementing augmented intelligence (AI) into clinical practice, taking steps to deliver the FutureTech programme and growing the global and operational footprint through the acquisitions of Global Diagnostics Ireland and RadMD, and increasing our potential reporter capacity through our Australian joint venture, MedX. The Board looks forward to seeing and supporting further execution of the Company's strategy during the rest of 2021 and hopes that, as the continued success of Covid-19 immunisation programmes reduces pressure on healthcare systems, the Company's positive start to 2021 continues."


Stuart Quin, CEO, will make a short presentation of the Company's strategy as set out in the 2021 Annual Report published on 25 May 2021.


No new information will be presented at the meeting.



For further information, please contact:  


Medica Group Plc:

Roy Davis, Chairman


+44 (0)33 33 111 222


Investec Bank plc (Joint Broker)

Sara Hale

Daniel Adams

Virginia Bull


+44 (0)20 7597 5970

Liberum (Joint Broker)

Bidhi Bhoma

Richard Lindley

Euan Brown


+44 (0)20 3100 2000

FTI Consulting

Victoria Foster Mitchell

Sam Purewal


+44 (0)20 3727 1000



About Medica Group PLC


Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.


Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition, Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.


The Company currently offers two primary services to hospital radiology departments:


· NightHawk - urgent reporting service

· Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.


These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.


Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.


For more information please visit:  


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t